Heartflow, Inc. - Common Stock (HTFL)

SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026.

Issued on behalf of VentriPoint Diagnostics Ltd.

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform

HeartFlow delivers AI-powered cardiac diagnostics to hospitals worldwide; a key insider recently trimmed their stake, SEC filings show.

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics to healthcare providers seeking advanced imaging and decision support tools.

MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025.

MOUNTAIN VIEW, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced new clinical evidence and a landmark registry launch that together advance the company's vision of transforming CAD management across every stage of the patient journey. At the American College of Cardiology (ACC) Annual Scientific Session, Heartflow is presenting new clinical evidence that further establishes AI-powered Heartflow Plaque Analysis as the leading tool for identifying high-risk patients earlier and guiding more effective medical management.

MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET.

MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026.

NBA legend Muggsy Bogues joins effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow Analysis

CEO Brent Ness noted a broad global market, with approximately 266 million people affected by chronic low back pain.

Issued on behalf of VentriPoint Diagnostics Ltd.

Fourth major national payer releases positive comprehensive coverage for AI-powered Heartflow Plaque Analysis

MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.

AI-powered cardiac diagnostics firm HeartFlow reported a recent insider buy, as disclosed in the latest SEC filing.

A key FDA-cleared analysis tool earned professional accolades for its utility.

Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment

Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National Health Service

One family office fund just made Karman its biggest reported equity bet—here’s what long-term investors should take from the move.

A billionaire family office has made a big bet on a newly public AI-driven heart diagnostics company—here’s what long-term investors should take from the move.

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference. The fireside chat will take place on Wednesday, December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET.

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.